Heterozygous RUNX1 R174* mutation in OCI-AML2 depletes mRNA expressions of Myc target genes, gene sets involved in ribosome and tRNA pathways, and alters the polysome profile compared with parental OCI-AML2 cells. (A) RNA-Seq analysis was performed on OCI-AML2 and OCI-AML2 RUNX1^R174*/wt (biologic duplicates). Heat map shows the number of mRNAs depleted or induced >1.25-fold and P value < .05 in the OCI-AML2 RUNX1^R174*/wt compared with OCI-AML2 cells. (B-C) Log2 fold-change in mRNA expression levels of HALLMARK_MYC_TARGETS (V1 and V2) and GO: Ribosome gene sets in OCI-AML2 RUNX1^R174*/wt compared with OCI-AML2 cells. (D) GSEA analysis and NES of OCI-AML2 RUNX1^R174*/wt cell mRNA expressions compared with other ribosomal/tRNA-associated pathways. All false discovery rate (FDR) q-values <0.1. (E) Representative GSEA plots for OCI-AML2 RUNX1^R174*/wt cell mRNA expressions compared with GO: Ribosome pathway. FDR q-value <0.1. (F) Polysome profiling of OCI-AML2 and OCI-AML2 RUNX1^R174*/wt cells. The positions of the 40S, 60S, 80S, and polysomes in OCI-AML2 RUNX1^R174*/wt relative to OCI-AML2 cells are noted. (G) RiboLace analysis was performed on OCI-AML2 and OCI-AML2 RUNX1^R174*/wt cells. GSEA was performed against GO pathways utilizing the differentially translated mRNA signature in OCI-AML2 RUNX1^R174*/wt vs OCI-AML2. Normalized enrichment scores are shown. All q-values are <0.1. (H) Log2 fold-change in actively translated mRNA (RiboLace) in OCI-AML2 RUNX1^R174*/wt over OCI-AML2 cells compared with GO_Ribosome gene set.